Close

Lilly (LLY) and Incyte's (INCY) Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. HCP
6. SPY
7. BSX
8. NOW
9. PI
10. ORCL


Go back to Lilly (LLY) and Incyte's (INCY) Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study

Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study

April 20, 2021 6:45 AM EDT

INDIANAPOLIS, April 20, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). The data are consistent with findings... More